VigenCell Presents Gamma Delta T Cell Therapy 'VR-CAR' at American Cancer Society Meeting

[Asia Economy Reporter Lee Gwan-joo] VigenCell announced on the 14th that it presented the research results of its pipeline 'VR-CAR,' which targets blood cancers and various solid tumors, in a poster session at the American Association for Cancer Research (AACR).

At this AACR, VigenCell presented a poster verifying the efficacy evaluation results of a new intracellular signaling domain that induces immune cell anti-cancer activation and the chimeric antigen receptor containing this domain.

The key content confirmed the killing efficacy against various types of human cancer cells in in vitro experiments of CAR-gamma delta T cells containing the CD30 co-stimulatory domain cells. The company explained that this CD30 co-stimulatory domain can be fused with antibody regions recognizing various tumor antigens to create a CAR structure, which can be utilized in developing CAR-gamma delta T cell therapies (VR-CAR) not only for blood cancers but also for solid tumors in the future.

Using this technology, VigenCell is currently conducting preclinical studies on the pipeline 'VR-GDT,' which targets liver cancer, in addition to 'VR-CAR,' the main pipeline of the gamma delta T cell therapy platform ViRanger™.

Tae-gyu Kim, CEO of VigenCell, said, "Starting with the presentation of 'VR-CAR' at AACR, we will gradually highlight VigenCell's presence in the global market."

This content was produced with the assistance of AI translation services.